Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract ...
To determine the factors that influence component survival we followed a large number of consecutive primary total hip arthroplasties performed in the same Institute. The cohort was large enough to be ...